Dermata Therapeutics (DRMA) Total Current Liabilities (2020 - 2021)
Dermata Therapeutics (DRMA) posted quarterly Total Current Liabilities of $1.5 million for Q4 2021, down 59.91% year-over-year from $3.8 million in Q4 2020, and up 26.91% quarter-over-quarter from $1.2 million in Q3 2021.
Dermata Therapeutics (DRMA) Total Current Liabilities (2020 - 2021) Analysis & Trends
Dermata Therapeutics' Total Current Liabilities history runs 2 years deep, the most recent figure standing at $1.5 million for Q4 2021.
- In Q4 2021, Total Current Liabilities fell 59.91% year-over-year to $1.5 million; the TTM figure through Dec 2021 stood at $1.5 million (down 59.91% YoY), while the FY2021 annual figure was $1.5 million, down 59.91% from the prior year.
- Total Current Liabilities for Q4 2021 stood at $1.5 million, up from $1.2 million in the prior quarter.
- The five-year high for Total Current Liabilities was $3.8 million in Q4 2020, with the low at $1.2 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Dermata Therapeutics | 5.33 Mn | 5.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.52 Mn |
| Sep 30, 2021 | 1.20 Mn |
| Jun 30, 2021 | 1.64 Mn |
| Dec 31, 2020 | 3.78 Mn |